“In the past year, our team has worked tirelessly, delving deep into the mechanisms of cancer and exploring new treatment strategies. Today, I am proud to announce that we’ve developed a ‘Long–acting Drug“,” Brendan said, his voice brimming with pride.


    “This ‘Long–acting Drug‘ not only exhibits a high level of specificity, precisely targeting cancer cells, but it also maintains therapeutic effects in the body for an extended period. This means cancer patients can expect longer survival times and an improved quality of life.”


    Brendan’s announcement was met with enthusiastic apuse and


    cheers from the audience.


    As Brendan finished his speech, other researchers began presenting their findings.


    Caroline was the fifth speaker. Dressed in a simple whiteb coat with her hair neatly tied back, she projected a professional and capable image.


    She started by disying a series of detailed experimental data charts.


    Pointing to the data on the screen<b>, </b>she exined, “These are the results of the in vitro and in vivo experiments we’ve conducted over the past few months on the ‘Long–acting Drug‘.


    “From this data, we can see that the ‘Long–acting Drug‘


    demonstrates significant effectiveness in inhibiting the growth and spread of cancer cells.”


    Caroline then presented photos and videos of theb animals.


    “After treatment with the ‘Long–acting Drug‘, the tumors in these animals have significantly reduced in size, and no major side effects. have been observed. This further confirms the drug’s safety and efficacy. However, it will still be some time before this drug can be brought to market,” she concluded.


    Caroline’s presentation generated great interest among the audience, with many people eager to learn more about the “Long-


    acting Drug“.


    She patiently answered each question.


    As the conference progressed, discussions about the “Long–acting Drug” became increasingly intense. Even after the conference concluded, the audience seemed eager for more information.


    The conference was not solely focused on drug research. advancements. High–profile figures from Saintornia were also in attendance. Drug development required significant funding, and potential sponsors could greatly alleviate the financial burden of


    research.


    After the conference ended, Caroline walked over to N with a smile and asked, “N, how did I do? Did I seem too nervous?”


    N shook her head and answered seriously, “Not at all, Caroline. You did great.”


    A brief sh of regret appeared in N’s eyes. If she hadn’t abandoned her rmendation to stay in academia and returned to Saintornia, she might have been among them now.


    However, she quickly dismissed that thought–starting over was still


    possible.


    Caroline smiled, about to speak, when a gentle female voice called from behind her, ‘Caroline,e over here. I want to introduce you to a few people.”


    They all turned to see who had spoken and saw Damon and the others standing next to Caroline’s mentor.


    N’s expression remained calm. Belonging to N?velDrama.Org.


    Melody, standing beside her, couldn’t help but whisper as Caroline walked away, “N, do you think Mr. Sumner is doing this on purpose? He knew you’d be here, so he brought Reba to rub it in your face!”


    N nced at Melody’s indignant expression and managed a small smile before dismissing the idea. “You’re overthinking it. I’m not that important. One of the purposes of this conference is to attract funding for research. Mr. Sumner was probably invited for that reason.”